Exclusionary data, inclusionary appeals
Gender and equity in an HIV-prevention clinical trial
Bibliographic Data
| ID | 7474413 |
|---|---|
| Authors | Jason V D''Amour (0000-0001-9257-720X, Florida State University, Tallahassee, FL, USA, corresponding author), Miranda R Waggoner (0000-0002-3460-6655, Rice University, Houston, TX, USA) |
| Year | 2026 |
| Volume | 56 |
| Issue | 1 |
| Pages | 96-118 |
| Publication date | 2026-02-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Social Studies of Science (JOURNAL) |
| Journal identifiers | ISSN: 0306-3127 • E-ISSN: 1460-3659 |
| Publisher | SAGE Publications (PUBLISHER • US) |
| DOI | 10.1177/03063127251349231 |
| PMID | 40577115 |
| OpenAlex | W4411715712 |
| Language | EN |
| References cited | 45 |
Despite the social and regulatory expectation that contemporary clinical trials for new pharmaceutical drugs will include a diverse set of research participants, achieving appropriate representation in clinical research remains tenuous. Of ongoing concern is how experts and regulators navigate decisions about drug approvals when presented with clinical studies that have limited demographic data. Drawing on regulatory discussions about Descovy, an HIV-prevention drug that was studied only in cisgender men and transgender women who have sex with men, we analyze a contentious debate over the meaning and impact of including and excluding certain populations from clinical trial design. Extending prior work in science and technology studies on how epistemological frameworks in clinical trials matter for concerns about the production of knowledge and social justice, we show how different conceptualizations of inclusion and equity (specifically, equity in data versus equity in access) come into tension in deliberations over pharmaceutical drug approvals. We argue that the discursive conflict over gender and inclusionary/exclusionary research practices that emerged in the case of Descovy points to an underappreciated feature of equity—temporality—that should be attended to when examining knowledge production in 21st-century clinical and regulatory landscapes
Clinical trial · Criminal justice · Criminology · Equity (law · Family medicine · Gender equity · Human immunodeficiency virus (HIV · Political science · Public relations · Social science · Sociology · Transgender · Ethics in Clinical Research · Feminist Epistemology and Gender Studies · Gender Studies · Law · Medicine · Psychology · Race, Genetics, and Society
Zero Trimester
Reputation and Power
Pharmocracy
Inclusion
The Logic of Care
Fatal Invention
Remaking a Life: How Women Living With HIV/Aids Confront Inequality
Adjudicating non-knowledge in the Omnibus Autism Proceedings
Swinging on the Pendulum
On the Heels of Ignorance
Race Decoded
When Experiments Travel
The second wave
How Can the Experiences of Black Women Living With HIV Inform Equitable and Respectful Reproductive Health Care Delivery
It just becomes much more complicated”
Cultural discourses and HIV/Aids activists’ meanings about PrEP
Co-production, multiplied
Making up ‘Vulnerable’ People
Homo adhaerens
Making a ‘sex-difference fact’
Challenging Assumptions About Minority Participation in US Clinical Research
Gendered Logics of Biomedical Research
Better Safe Than Sorry
How pharmaceutical industry funding affects trial outcomes
The logic of strategic ignorance
Strategies of inclusion
Uncertain and under Quarantine
Impure Science
Equality versus Reproductive Risk
Saying 'No' to PrEP research in Malawi
Agency-Without-Choice
| Citation velocity | historical |
|---|---|
| Highly cited | No |